Chronic pancreatitis (CP) is a predisposing condition for pancreatic ductal adenocarcinoma (PDAC), the most common and deadly cancer of the pancreas. However, the link between CP and PDAC is not known.
Aug 19, 2019
0
1
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the world. Mostly chemoresistant, PDAC so far has no effective treatment. Understanding the connective tissue, called stroma, ...
Jun 13, 2019
0
13
Researchers from the Experimental Oncology Group, led by Mariano Barbacid at the Spanish National Cancer Research Centre (CNIO), have published in Cancer Cell the results of a study that shows full regression of advanced ...
Apr 12, 2019
0
8
(HealthDay)—Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of ...
Apr 4, 2019
0
2
An experimental drug may be effective against a deadly form of pancreatic cancer when used in combination with other immune-boosting therapies, according to a cover study publishing online Nov. 12 in Cancer Cell.
Nov 12, 2018
0
1
Surrey's BioProChem group has developed a biomaterial based complex synthetic tissue, which is aimed at replicating the way pancreatic cancer tumours develop within the body.
Nov 9, 2018
0
0
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy. The answer may lie in treating a protein found in the scar-type tissue called stroma ...
Oct 24, 2018
0
89
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center—Jefferson Health and Lankenau Institute for Medical Research scientists find ...
Oct 22, 2018
0
15
A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai.
Sep 25, 2018
0
3
The effects of KRAS mutations underlying many different types of cancer are more diverse than previously thought, according to a new study led by the University of Eastern Finland. Different mutations in the same amino acid ...
Sep 11, 2018
0
50
